AnaptysBio Appoints New CFO, Two Directors; Sets Key FDA PDUFA Date for Imsidolimab

summarizeSummary

AnaptysBio announced new executive and board appointments, provided a specific FDA PDUFA date for imsidolimab, and updated on Jemperli royalty performance following its spin-off.

check_boxKey Events

• New Leadership Appointments

  Chris Murphy has been appointed as the new Chief Financial Officer. Additionally, Susannah Gray (former CFO of Royalty Pharma) and Owen Hughes (CEO of XOMA Royalty) have joined the Board of Directors, bringing significant biopharmaceutical finance and investment experience.

• Imsidolimab FDA PDUFA Date Set

  The FDA has set a target action date (PDUFA) of December 12, 2026, for imsidolimab in generalized pustular psoriasis (GPP), providing a clear regulatory timeline for this key asset.

• Jemperli Royalty Performance Update

  GSK reported strong Q1 2026 Jemperli sales of $313 million, representing over 40% year-over-year growth. AnaptysBio anticipates the remaining ~$325 million non-recourse debt monetization will be paid down by the end of Q2 2027.

• First Quarter 2026 Financial Results

  The company reported a net loss of $52.9 million, or $1.84 per share, for Q1 2026. General and administrative expenses increased due to legal costs associated with the company's recent spin-off and ongoing litigation.

auto_awesomeAnalysis

This filing details significant leadership changes for AnaptysBio following its recent spin-off, including a new Chief Financial Officer and two new Board members. It also provides a specific FDA PDUFA date for imsidolimab, a key regulatory milestone for one of its core royalty assets. These updates clarify the company's new strategic direction and future value drivers as it transitions to a royalty-focused business model.